Trinity Biotech | TRIB - Cash And Equivalent


Trinity Biotech reported $1.34M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Abbott USD 8.52B 1.01B Dec/2025
Bayer EUR 5.9B 1.34B Sep/2025
Bio-Rad Laboratories USD 529.8M 134M Dec/2025
EDAP TMS EUR 29.84M 4.35M Dec/2024
J&J USD 21.69B 1.98B Mar/2026
Mesa Laboratories USD 28.98M 8.55M Dec/2025
OraSure Technologies USD 199.28M 17.2M Dec/2025
Plus Therapeutics USD 4.26M 9.03M Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Siemens EUR 14.5B 146M Sep/2025
Surmodics USD 36.11M 11.81M Sep/2024
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Tosoh JPY 133.1B 10.44B Sep/2025
Trinity Biotech USD 1.34M 3.83M Sep/2025
Veracyte USD 362.58M 47M Dec/2025